Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)
This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
First received: January 26, 2011
Last updated: July 23, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2011|
|Primary Completion Date:||November 2011 (Final data collection date for primary outcome measure)|